PTC Therapeutics (NASDAQ:PTCT) reported Q4 EPS of ($2.35), $0.78 worse than the analyst estimate of ($1.57). Revenue for the quarter came in at $167.4 million versus the consensus estimate of $190.38 million.
GUIDANCE:
PTC Therapeutics sees FY2023 revenue of $0.94-1 billion, versus the consensus of $0.9 billion.